journal article·2026-07-13

Construction of an Infection-Inflammation Microenvironment-Regulating Nano-antimicrobial Agent and Application in the Treatment of Burn Wounds Complicated with Multidrug-Resistant Staphylococcus aureus Infection

Huifeng Qian, Xiaoyu Pan, Shujie Liang, Sheliang Wang, Debao Yu, Jinyun Lu, Shunchang Li, Xinyi Jin, Haijiang Tong, Zhangsen Yu

Publisher page

Abstract

Burn wounds are highly susceptible to bacterial colonization, particularly by multidrug-resistant pathogens, which often result in refractory infections, excessive inflammation, and delayed healing. Herein, we report the rational design and construction of a multifunctional nano-antimicrobial agent, designated mPB@PHMB, through the co-assembly of mesoporous Prussian blue (mPB) with the polymer polyhexamethylene biguanide (PHMB). The resultant nanocomposite integrates potent antibacterial activity with the capacity to modulate the inflammatory microenvironment. Notably, mPB@PHMB exhibited pronounced bactericidal efficacy against methicillin-resistant Staphylococcus aureus (MRSA). Benefiting from the intrinsic multi-enzyme-mimetic activities of mPB, the nanocomposite efficiently scavenged intracellular reactive oxygen species, thereby alleviating oxidative stress-induced cellular injury. Transcriptomic profiling and protein analyses revealed that mPB@PHMB markedly suppressed the NF-κB pathway activation, attenuated lipopolysaccharide-induced M1 macrophage polarization, and reduced the production of pro-inflammatory cytokines. Biocompatibility assessments demonstrated negligible acute cytotoxicity toward skin fibroblasts and no overt toxicity in healthy C57BL/6 mice, underscoring the favorable safety profile of mPB@PHMB. Furthermore, in a murine model of MRSA-infected burn wounds, topical treatment with mPB@PHMB reduced the bacterial burden by approximately 90%. Concurrently, treatment with mPB@PHMB substantially decreased the proportion of M1-polarized macrophages, suppressed the expression of inflammatory cytokines, and alleviated the inflammatory milieu within the wound bed, thereby accelerating tissue repair and wound closure. Collectively, these findings establish mPB@PHMB as a promising nano-therapeutic platform that synergistically couples antimicrobial action with immunomodulatory functions, offering a robust and translatable strategy for the management of burn wounds complicated by multidrug-resistant bacterial infection.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Wound Healing and Treatments · Cancer Research and Treatments · Bacterial biofilms and quorum sensing

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Clinical Laboratory Center

Shaoxing Second Hospital

Key Laboratory of Ministry of Education for Gastrointestinal Cancer

Fujian Medical University

Shaoxing People's Hospital

Laboratory of Nanomedicine, Medical Science Research Center, School of Medicine

Shaoxing University

Funding

Zhejiang Province Traditional Chinese Medicine Science and Technology Project · Medical and Health Science Program of Zhejiang Province

References (34)

Show source-provided references
1. 10.1038/s41572-020-0145-510.1038/s41572-020-0145-5 ↗
2. 10.1097/PRS.000000000001059510.1097/PRS.0000000000010595 ↗
3. 10.1002/adma.20251585410.1002/adma.202515854 ↗
4. 10.1016/j.mtbio.2025.10168610.1016/j.mtbio.2025.101686 ↗
5. 10.1002/adfm.20241679110.1002/adfm.202416791 ↗
6. 10.1016/j.mtbio.2025.10243010.1016/j.mtbio.2025.102430 ↗
7. 10.1016/j.carbpol.2025.12428510.1016/j.carbpol.2025.124285 ↗
8. 10.1186/s12951-023-02144-210.1186/s12951-023-02144-2 ↗
9. 10.1016/j.cej.2024.15063210.1016/j.cej.2024.150632 ↗
10. 10.1002/adma.20240136910.1002/adma.202401369 ↗
11. 10.1016/j.nanoen.2025.11151410.1016/j.nanoen.2025.111514 ↗
12. 10.1016/j.addr.2023.11476910.1016/j.addr.2023.114769 ↗
13. 10.1093/burnst/tkaf04010.1093/burnst/tkaf040 ↗
14. 10.1002/advs.20241303210.1002/advs.202413032 ↗
15. 10.1186/s12951-019-0514-y10.1186/s12951-019-0514-y ↗
16. 10.1016/j.actbio.2025.07.06510.1016/j.actbio.2025.07.065 ↗
17. 10.1021/acsami.5c0722910.1021/acsami.5c07229 ↗
18. 10.1021/acsami.3c0951610.1021/acsami.3c09516 ↗
19. 10.1016/j.jconrel.2025.11375510.1016/j.jconrel.2025.113755 ↗
20. 10.1002/adhm.20220078710.1002/adhm.202200787 ↗
21. 10.1021/acsami.4c0430210.1021/acsami.4c04302 ↗
22. 10.1021/acsami.1c2456910.1021/acsami.1c24569 ↗
23. 10.1002/smll.20240115210.1002/smll.202401152 ↗
24. 10.1016/j.jhazmat.2021.12511010.1016/j.jhazmat.2021.125110 ↗
25. 10.1016/j.cej.2021.12870710.1016/j.cej.2021.128707 ↗
26. 10.1016/j.ijpharm.2024.12377910.1016/j.ijpharm.2024.123779 ↗
27. 10.1002/advs.20251077410.1002/advs.202510774 ↗
28. 10.1021/acsami.5c1787810.1021/acsami.5c17878 ↗
29. 10.1016/j.mattod.2024.08.01010.1016/j.mattod.2024.08.010 ↗
30. 10.1016/j.ijbiomac.2025.14782410.1016/j.ijbiomac.2025.147824 ↗
31. 10.1039/D3PY01148H10.1039/D3PY01148H ↗
32. 10.3389/fbioe.2026.176564710.3389/fbioe.2026.1765647 ↗
33. 10.3389/fimmu.2021.79175310.3389/fimmu.2021.791753 ↗
34. 10.1016/j.msec.2009.01.00210.1016/j.msec.2009.01.002 ↗